Not surprised that GSK abandoned IV Relenza. Their profit is from new vaccines every year. Better for GSK than to find a heap of generic IV Relenza look-a-like vaccine alternatives flooding their market when the patent expires in 2014. GSK cannot serve BTA when it has only one master - GSK.
- Forums
- ASX - By Stock
- BTA
- lani, iv relenza,flumist breaking news reuters
lani, iv relenza,flumist breaking news reuters, page-6
-
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BTA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
SPONSORED BY The Market Online